hs-20093
mAbexperimentalADC
Clinical trial activity
24 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
14
Phase 2
12
Phase 3
4
Phase 4
0
Earliest trial started Nov 28, 2021 (NCT05276609)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Colorectal Neoplasms · Phase 1
- Gastrointestinal Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 3
- Neoplasms · Phase 2
- Osteosarcoma · Phase 3
- Ovarian Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 2
- Sarcoma · Phase 2
- Small Cell Lung Carcinoma · Phase 3
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
Mechanism of action
- CD276 antigenBINDING AGENT
B7-H3
Chemistry & pharmacology
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07268053 | Early Phase 1 (Phase 1) | Jan 31, 2026 | GlaxoSmithKline, Ivy Brain Tumor Center, University of Arizona |
| NCT07277270 | Phase 1/Phase 2 (Phase 2) | Dec 8, 2025 | GlaxoSmithKline |
| NCT07230106 | Phase 2 | Nov 30, 2025 | Hengrui Therapeutics, Inc. |
| NCT07186452 | Phase 1 | Sep 30, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT07115446 | Phase 1 | Aug 31, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT07099898 | Phase 3 | Aug 11, 2025 | GlaxoSmithKline |
| NCT07063407 | Phase 1 | Jul 31, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06885034 | Phase 1/Phase 2 (Phase 2) | Jun 11, 2025 | GlaxoSmithKline |
| NCT06963502 | Phase 1 | May 30, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06769425 | Phase 1 | May 7, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06935409 | Phase 3 | Apr 30, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06699576 | Phase 1 | Dec 20, 2024 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06621563 | Phase 1 | Dec 1, 2024 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06825624 | Phase 1 | Oct 3, 2024 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06526624 | Phase 3 | Sep 30, 2024 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06551142 | Phase 1 | Aug 30, 2024 | GlaxoSmithKline |
| NCT06498479 | Phase 3 | Jul 4, 2024 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06332170 | Phase 1 | Apr 26, 2024 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06112704 | Phase 2 | Jan 31, 2024 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06052423 | Phase 2 | Nov 30, 2023 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Showing 20 of 24 trials
Page 1 / 2
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 18 | 18 | 3 | 2021 |
| GlaxoSmithKline | For profit | 5 | 4 | 3 | 2024 |
| Henan Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Hengrui Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2025 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Ivy Brain Tumor Center | Academic/Hospital | 1 | 0 | 1 | 2026 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Tianjin Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Arizona | Academic/Hospital | 1 | 1 | 1 | 2026 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2023 |
12 organizations
Page 1 / 1